Physician profile
Marcus W Lee
NPI 1457364077
$1,855.54
in general payments reported to CMS, 2019-2025
29 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2021: $20.00 · 2024: $352 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $430.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $155.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $148.11 | 2019-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $134.26 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.79 | 2019 | |
| Amgen INC. | $95.36 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $74.07 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.63 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $70.20 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $65.19 | 2019-2025 | Verquvo |
| Pfizer INC. | $61.27 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $57.53 | 2019 | |
| Boston Scientific Corporation | $51.51 | 2024 | Wavewriter Alpha Prime 16 |
| E.R. Squibb & Sons, L.L.C. | $49.34 | 2019 | |
| Lilly USA, LLC | $43.77 | 2019-2025 | Mounjaro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $30.06 | 2019 | |
| Glaxosmithkline, LLC. | $29.68 | 2024 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.07 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $27.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.10 | 2019 | |
| Valeritas, INC. | $22.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.08 | 2024 | Voquezna |
| Hikma Pharmaceuticals USA | $15.44 | 2024 | Ryaltris |
| Bausch Health US, LLC | $14.64 | 2019 | |
| Eisai INC. | $14.15 | 2025 | |
| Mylan Specialty L.P. | $11.80 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.